Analyst recommendations for ABT
Abbott Laboratories (ABT) has recorded strong growth recently, registering stellar performance even amid the integration challenges of its large acquisitions of St. Jude Medical and Alere, which also went through a period of trouble with a series of litigations. On January 24, Abbott Laboratories posted strong 4Q17 and fiscal 2017 results. Then the stock hit a 52-week high on January 25. For details, see Inside Abbott Laboratories’ 4Q17 Earnings Results: Key Highlights.
As of February 19, as per 21 analysts who took part in a recent Reuters survey, ABT stock has a “strong buy” rating from ~33% of Wall Street analysts (seven), and ~48% (ten) have a “buy” recommendation. The remaining 71% (four) have a “hold” rating on Abbott Laboratories. The company isn’t rated a “sell” by any analysts.
For a 12-month recommendation summary on ABT stock, check out the above table. As of February 19, the consensus 12-month target price for ABT stock is $68.22, which implies a 12-month investment return potential of ~13.4%. ABT stock closed trading at $60.17 per share on February 16.
Revisions and updates
Royal Bank of Canada, Guggenheim, and Leeerink Swan have a “buy” recommendation on ABT stock. These firms reiterated their positive outlook on the stock after robust 4Q17 earnings results on January 24. Also, Citigroup has shown increased confidence in the stock, raising its price target from $59 to $64 on January 30. However, its recommendation on ABT stock remains “neutral.”